Anti-CA19-9/Sialyl Lewis A (sLeA) Antibody (BSA and Azide free)

CA19-9/ Sialyl Lewis a (sialyted lacto-N-fucopentose) (α-NeuNAc- (2→3) -β-D-Gal- (1→3) - (α-L-Fuc-[1→4]) -D-GlcNAc, 3′-SLea) corresponds to blood group antigens. In normal tissue Sialyl Lewis a is present in ductal epithelium of the breast, kidney and salivary glands. This antigen is expressed is increased in all gastrointestinal carcinomas (stomach, intestine and pancreas) (1) While it is not useful to diagnose particular forms of cancer, specifically pancreatic cancer, it may be useful to monitor the results of treatment and to determine whether the disease may be recurring (3) Other causes for elevated CA19-9 levels include Mirizzi’s syndrome and other hepatobiliary diseases (2) In patients that do not have the Lewis antigen blood type (about 5% of the population), CA19-9 is not elevated in pancreatic cancer even with large tumors because they have a deficiency of fucosyltransferase that is needed to produce CA19-9 (1) .

Our Anti-CA19-9/Sialyl Lewis A (sLeA) mouse monoclonal primary antibody from Antibodies Incorporated is produced in-house from hybridoma clone CA19-9-203. It detects human CA19-9/Sialyl Lewis A (sLeA), and is purified by protein a chromatography. It is great for use in WB, IHC, ICC, ELISA.

Aliquot and store at ≤ -20°C for long term storage. For short term storage, store at 2-8°C. For maximum recovery of product, centrifuge the vial prior to removing the cap.

Produced by in vitro bioreactor culture of hybridoma line followed by Protein A affinity chromatography and buffer exchanged into 1X PBS. Purified mAbs are >90% specific antibody.

Each new lot of this antibody is tested to confirm that it recognizes a single immunoreactive band of expected molecular weight when used in Western blot.